Neuropathic pain is caused by a disease or injury to the neurological system and encompasses a wide range of chronic illnesses that affect up to 8% of the population.
A large corpus of nerve pain research indicates to various major contributory mechanisms, such as abnormal ectopic activity in nociceptive nerves, peripheral and central sensitization, defective inhibitory regulation, and pathological activation of microglia.
To detect distinctive signs and symptoms of neuropathic pain
A comprehensive history and physical examination are required. Other laboratory studies and clinical neurophysiological testing may assist identify the underlying cause and guide treatment selection in many cases.
Treatment of neuropathic pain
Treatments are primarily symptomatic and may include nonpharmacological, pharmacological, and interventional therapy. Pharmacological treatment has the most substantial data, and currently recommended first-line medications include Generic Lyrica.
Individualized multidisciplinary patient care is made possible by careful consideration of pain-related disability (for example, depression and occupational dysfunction), as well as patient education, repeat follow-up and strategic referral to appropriate medical/surgical subspecialties, and physical and psychological therapies.
Continued preclinical and clinical research and development are expected to lead to further advances in the diagnosis and treatment of neuropathic pain in the near future.
CME Participation
The intended audience is: The primary audience for Mayo Clinic Proceedings is internal medicine physicians and other clinicians who want to increase their clinical medicine knowledge and stay up to date on medical research developments.
Statement of Need: General internists and primary care physicians must have a broad knowledge base spanning all body systems as well as frequent and rare illnesses. Mayo Clinic Proceedings intends to harness its authors’ experience to help physicians comprehend best practises in the diagnosis and management of clinical problems.
Accreditation: The Accreditation Council for Continuing Medical Education has accredited Mayo Clinic College of Medicine to conduct continuing medical education for physicians.
Medicine designates
Physicians should claim just the credit that is proportionate to their participation in the activity.
Learning Objectives: After reading this article, you should be able to The identiy key pathophysiologic mechanisms involved in the development of neuropathic pain, (2) use the appropriate clinical tools to assess patients with neuropathic pain, and (3) formulate an evidence-based approach for the pharmacologic treatment of neuropathic pain.
This study covers a wide range of therapeutic options, many of which are not necessarily labelled for use in the treatment of neuropathic pain in all countries. As a result, readers are expected to determine the labelled indications for any of the presented treatments in their country of clinical practise.
Participation Method
The International Association for the Study of Pain recently classified neuropathic pain as “pain induced by a lesion or disease of the somatosensory system.”
Nociceptive pain (for example, arthritis) is caused by peripheral sources of noxious stimulation (for example, inflammatory mediators) that are processed by an otherwise normal somatosensory system, whereas nerve pain is caused by a lesion or disease that results in an abnormal and dysfunctional somatosensory system. 2 With this description in mind, nerve pain refers to a wide range of clinical diseases (Table 1)3 that can be classified anatomically (e.g., peripheral vs. central) and etiologically (eg, degenerative, traumatic, infectious, metabolic, and toxic).
Neuropathic Pain Classification Based on Major Pathology Source: Lancet Neurol3, with permission.
- Pathology
- Peripheral Spinal Brain
- Genetic
- Neuropathy of Fabry
- Syringomyelia
- Syringobulbia
- Metabolic
- Diabetic neuropathy is excruciatingly painful.
- Myelopathy caused by B12
- Injuries to the Nerves
- Injury to the spinal cord
- Multiple sclerosis (MS)
- Neuropathy of the vasculature
- Stroke of the spinal cord
- Stroke of the brain
- Neoplastic
Neuropathy caused by tumour compression
- Compression of a tumour
- Compression of a tumour
- Immunological
- The syndrome of Guillain-Barré
- Multiple sclerosis (MS)
- Multiple sclerosis (MS)
- Borreliosis, HIV infection
- Myelitis caused by infection
- Encephalitis \sToxic
Neuropathy caused by chemotherapy
Both stimulus-independent (“spontaneous”) and stimulus-dependent (“evoked”) pain, as well as other symptoms such as tingling, are examples of “positive” signs of nerve pain syndromes (ie, paresthesias).
Numbness, weakness, and loss of deep tendon reflexes in the affected nerve region are examples of “negative” signs and symptoms that may be noted.
Given the variety of associated clinical categories, describing the epidemiology of nerve pain is especially difficult. However, the validation of a number of diagnostic techniques for identifying pain with nerve characteristics is still ongoing.
Diagnosis and Treatment of Neuropathic Pain Mechanisms
Understanding the various pathways of pain transmission and pain modulation. Effective clinical assessment as well as nerve pain treatment with Pregalin 50mg.
Many sophisticated investigations have been facilitated by the development of several preclinical pain models involving injury (eg, surgical) or disease induction (eg, streptozocin-induced diabetic neuropathy) of peripheral or central neurons, providing a wealth of information about cellular and molecular mechanisms of nerve pain.
Human neuropathic pain investigations utilising quantitative sensory testing, electrophysiology, nerve and skin biopsies, and functional brain imaging have also revealed clinical signs of underlying nerve pain processes (e.g., sensitization and poor descending inhibition).
The following processes have been reported to be important in nervepain conditions: (1) ectopic activity, (2) peripheral sensitization, (3) central sensitization, (4) poor inhibitory regulation, and (5) microglia activation.
